Zachary Cooper, PhD
@zaccoop
Followers
522
Following
4K
Media
5
Statuses
2K
Senior Director/Translational Lead @ AstraZeneca & former Asst. Professor at MD Anderson Cancer Center. Immunotherapy Advocate. Working to end cancer. Go Blue!
Maryland, USA
Joined August 2012
342
240
1K
Congratulations to my colleagues at the International Neoadjuvant Melanoma Consortium INMC for receiving @sitcancer collaboration award. Grateful for recognition of relentless work since 2016 to advance neoadjuvant immunotherapy @Liz_htx03
1
4
17
Recently published: IPH5201, an Anti-CD39 Monoclonal Antibody, as Monotherapy or in Combination with #Durvalumab in Advanced #SolidTumors, by John Powderly et al. https://t.co/IexyaUHEZ5
@zaccoop #CD39 #OpenAccess
0
1
2
Honored & excited that the INMC is receiving the SITC 40th Anniversary Collaboration Award! Since 2016, this global effort has shaped melanoma care & sparked cross- cancer collaborations. Grateful to co lead w/ a tremendous team of leaders to make this shared vision possible!
Congratulations to Dr. Andres Salazar of @oncovir, along with the INMC, led by Dr. Elizabeth Burton of @MDAndersonNews, and the STAR Collaborative, led by Dr. Stephen Gottschalk of @StJude, recipients of 40th Anniversary Collaboration Awards. LEARN MORE: https://t.co/VQcfvkNGVe
2
5
17
I am thrilled to finally share my lab's first paper showing that sucralose consumption reduces immunotherapy efficacy in cancer, published NOW in @CD_AACR ! Let's break it down. 1/n https://t.co/B85rLv9HDD
10
22
96
Our manuscript using single cell RNA sequencing to compare two CD19 CAR T cell products, axi-cel and tisa-cel is online at JITC! @DrFredLocke @MoffittNews
https://t.co/cENQ8xCaDd . Our findings (thread):
jitc.bmj.com
Background Autologous CD19 chimeric antigen receptor (CAR) T-cell therapy leads to durable responses and improved survival in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL)....
4
21
73
Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non–Small Cell Lung Cancer Update From the COAST Randomized Clinical Trial in @JAMANetworkOpen @AstraZeneca
RCT: Combining durvalumab with oleclumab or monalizumab improved outcomes over durvalumab alone in unresectable stage III non-small cell lung cancer post-chemoradiotherapy. https://t.co/8xhk6lT4zL
@zaccoop
0
0
0
Final COMPASS trial data advanced #PDAC ➡️268 WGS& 253RNA-seq ➡️basal-like& hi GRIm-S ⬇️OS, both unique TME inc CD8 variation,NB primaries vs mets ➡️LTS :HRD, KRAS WT ➡️KRAS major enriches basal, >type II DM ➡️LAPC≠intact SMAD4 ➡️47% receive 2nd line tx https://t.co/wXcQY1kPvR
1
30
86
Delighted to share our new approach to enhance CAR T cell function in solid tumours published today @Nature. In this work we identify a new strategy to generate armoured CAR T cells.
nature.com
Nature - A CRISPR knock-in strategy that uses endogenous gene regulatory mechanisms can engineer ‘armoured’ CAR T cells that secrete proinflammatory cytokines directly within a tumour...
15
57
183
I’ve been in the exercise oncology field for 20 years and for all of that time, the main criticism has been “show me a well controlled RCT.” Well, here it is. Exercise following adjuvant chemotherapy for colon cancer reduced recurrence and improves OVERALL SURVIVAL! #ASCO25
Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:
12
66
403
Manufacturing CAR T cells in the laboratory is expensive and time-consuming. An in vivo approach could get this powerful therapy to more people https://t.co/aDkEVDlNtk
nature.com
Nature - Manufacturing CAR T cells in the laboratory is expensive and time-consuming. An in vivo approach could get the powerful therapy to more people.
2
44
129
Out now & open access in @NatureMedicine concurrent with presentation at #ASCO2025 is NeoCOAST-2! I have been delighted to collaborate on the first platform neoadjuvant trial in lung cancer led by Dr. Tina Cascone https://t.co/cEfflLR7qk ! #LCSM 1/6
1
43
132
One final thing. Harvard has launched an incredible effort to share the impact of the funding cuts with the public on their website landing page. We need more like this:
harvard.edu
Harvard University is devoted to excellence in teaching, learning, and research, and to developing leaders who make a difference globally.
8
49
158
Yesterday, we joined @AstraZenecaUS to celebrate a $300 million investment in their new cell therapy facility in Montgomery County —bringing 150 high-skilled jobs & new hope in the fight against cancer. It was great to be joined by the entire District 15 team Senator
1
7
18
My strongest support for Dr. Tina Cascone MD PhD who has been nominated for the @sitcancer board of directors election! She is a truly outstanding physician scientist, generous collaborator, leader in SITC and great human being! Please vote! https://t.co/wFTmmGkWDp
0
13
51
Amazing #AACR25 special evening Town Meeting "How AI Will Impact the Future of Pathology"! hosted by Dr. Massimo Loda. Featuring foundation models, agentic AI, benchmarking, multimodal data and drug development! @AI4Pathology, Jelle Wesseling, Kenneth Bloom & Jorge S. Reis-Filho
0
2
11
Onsite access to the full slate of Professional Development Series of Sessions taking place at the AACR Annual Meeting 2025 are available to registered AACR members at no additional cost. https://t.co/eL8aXbC4fs
0
5
9
Thrilled to share our latest study just out in @Nature 😄A major milestone in our collaboration with @Aiims1742 Led by brilliant @GuangshengPei @jiminmin_v @MDAndersonNews
nature.com
Nature - Spatially resolved transcriptomic profiling of primary tumours and metastases from patients with pancreatic cancer provides insight into the evolutionary progression to metastasis, and the...
13
70
288
Kicking off our keynote speaker series at #MoffittBoB today @MoffittNews. Thank you to our first keynote, Craig Maxwell, Senior Vice President, Head of Oncology R&D Strategy, Business Development & Academic Research Partnerships @AstraZeneca, who is discussing fostering
0
3
14